Silenseed, a leading RNAi-based therapeutics company, announced (April 14, 2015) that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 9,006,199) named “Methods and compositions for treating prostate cancer ” to be added to the company’s fast growing patent estate.